Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma

Differing doses of ipilimumab (IPI) are used in combination with an anti-PD1 antibody in advanced melanoma. There is no data on the outcomes of patients who progress following low-dose IPI (

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2023-06, Vol.186, p.12-21
Hauptverfasser:	Lai-Kwon, Julia, Jacques, Sarah, Carlino, Matteo, Benannoune, Naima, Robert, Caroline, Allayous, Clara, Baroudjian, Barouyr, Lebbe, Celeste, Zimmer, Lisa, Eroglu, Zeynep, Topcu, Turkan Ozturk, Dimitriou, Florentia, Haydon, Andrew, Lo, Serigne N., Menzies, Alexander M., Long, Georgina V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Alternative dosing Antineoplastic Combined Chemotherapy Protocols - adverse effects Humans Immunotherapy Ipilimumab Ipilimumab - adverse effects Melanoma Melanoma - pathology Middle Aged Neoplasms, Second Primary - drug therapy Nivolumab - adverse effects Retrospective Studies
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Differing doses of ipilimumab (IPI) are used in combination with an anti-PD1 antibody in advanced melanoma. There is no data on the outcomes of patients who progress following low-dose IPI (
ISSN:	0959-8049 1879-0852
DOI:	10.1016/j.ejca.2023.03.006